Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Disitamab Vedotin in HER2+ mCRC
NCT05333809Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin, pembrolizumab in metastatic colorectal cancer (mCRC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05333809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333809.